GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Innovus Pharmaceuticals Inc (OTCPK:INNV) » Definitions » Market Cap

Innovus Pharmaceuticals (Innovus Pharmaceuticals) Market Cap : $57.56 Mil (As of Apr. 27, 2024)


View and export this data going back to 2008. Start your Free Trial

What is Innovus Pharmaceuticals Market Cap?

Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Innovus Pharmaceuticals's share price for the quarter that ended in Sep. 2019 was $2.1. Innovus Pharmaceuticals's Shares Outstanding (EOP) for the quarter that ended in Sep. 2019 was 2.61 Mil. Therefore, Innovus Pharmaceuticals's market cap for the quarter that ended in Sep. 2019 was $5.49 Mil.

Innovus Pharmaceuticals's quarterly market cap declined from Mar. 2019 ($12.92 Mil) to Jun. 2019 ($3.92 Mil) but then increased from Jun. 2019 ($3.92 Mil) to Sep. 2019 ($5.49 Mil).

Innovus Pharmaceuticals's annual market cap declined from Dec. 2016 ($24.15 Mil) to Dec. 2017 ($13.98 Mil) but then increased from Dec. 2017 ($13.98 Mil) to Dec. 2018 ($14.86 Mil).

Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Innovus Pharmaceuticals's Enterprise Value for Today is $57.56 Mil.


Innovus Pharmaceuticals Market Cap Historical Data

The historical data trend for Innovus Pharmaceuticals's Market Cap can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Innovus Pharmaceuticals Market Cap Chart

Innovus Pharmaceuticals Annual Data
Trend Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18
Market Cap
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.88 3.30 24.15 13.98 14.86

Innovus Pharmaceuticals Quarterly Data
Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19
Market Cap Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 24.98 14.86 12.92 3.92 5.49

Competitive Comparison of Innovus Pharmaceuticals's Market Cap

For the Drug Manufacturers - Specialty & Generic subindustry, Innovus Pharmaceuticals's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Innovus Pharmaceuticals's Market Cap Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Innovus Pharmaceuticals's Market Cap distribution charts can be found below:

* The bar in red indicates where Innovus Pharmaceuticals's Market Cap falls into.



Innovus Pharmaceuticals Market Cap Calculation

Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.

Innovus Pharmaceuticals's Market Cap for the fiscal year that ended in Dec. 2018 is calculated as

Market Cap (A: Dec. 2018 )=Share Price (A: Dec. 2018 )*Shares Outstanding (EOP) (A: Dec. 2018 )
=$7.07*2.10128
=$14.86

Innovus Pharmaceuticals's Market Cap for the quarter that ended in Sep. 2019 is calculated as

Market Cap (Q: Sep. 2019 )=Share Price (Q: Sep. 2019 )*Shares Outstanding (EOP) (Q: Sep. 2019 )
=$2.1*2.61238
=$5.49

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Innovus Pharmaceuticals  (OTCPK:INNV) Market Cap Explanation

Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the company’s debt. The real price you pay is the Enterprise Value.

Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.


Innovus Pharmaceuticals Market Cap Related Terms

Thank you for viewing the detailed overview of Innovus Pharmaceuticals's Market Cap provided by GuruFocus.com. Please click on the following links to see related term pages.


Innovus Pharmaceuticals (Innovus Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
8845 Rehco Road, San Diego, CA, USA, 92121
Innovus Pharmaceuticals Inc is engaged in the healthcare industry. It is a specialty pharmaceutical company engaged in the commercialization, licensing and development of safe and effective non-prescription medicine and consumer care products to improve men's and women's health and vitality and respiratory diseases. Innovus distributes OTC medicines and consumer and health products directly, through commercial partners to primary care physicians, urologists, gynecologists and therapists, and directly to consumers through its on-line channels, retailers, and wholesalers.
Executives
Armistice Capital, Llc 10 percent owner 510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022
Armistice Capital Master Fund Ltd. 10 percent owner C/O ARMISTICE CAPITAL, LLC, 510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022
Steven Boyd 10 percent owner 510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022
Vivian H Liu director
Henry Jemil Esber director 38 ANGELL BROOK DRIVE, WEST BOYLSTON MA 01853
Randy Berholtz officer: EVP, CORPORATE DEVELOPMENT 6330 NANCY RIDGE DRIVE, SUITE 103, SAN DIEGO CA 92121
Ryan J Selhorn officer: VP, CFO 4275 EXECUTIVE SQUARE, SUITE 650, LA JOLLA CA 92037
Bassam Damaj director, officer: CHIEF EXECUTIVE OFFICER C/O BIO-QUANT, INC., 6330 NANCY RIDGE DRIVE, SUITE 103, SAN DIEGO CA 92121
Robert Hoffman officer: Chief Financial Officer ARENA PHARMACEUTICALS INC, 6166 NANCY RIDER DRIVE, SAN DIEGO CA 92121
Morgan R Brown officer: See remarks 420 CHIPETA WAY, SALT LAKE CITY UT 84108
Jacki Bartholomew director 175 SOUTH MAIN STREET, NO 1212, SALT LAKE CITY UT 84111
Thomas L Harkness director, officer: Secretary 175 SOUTH MAIN STREET, NO 1212, SALT LAKE CITY UT 84111
Wallace Boyack director, 10 percent owner, officer: President & CEO 175 S MAIN ST, NO 1212, SALT LAKE CITY UT 84111